Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

hVIVO says inoculation warrants further development after showing early promise

National Institutes of Health has released part of the data set from a phase I study
mosquito
The company is developing a vaccine for mosquito-borne diseases

hVIVO PLC (LON:HVO) said its vaccine for mosquito-borne diseases “warrants further development”.

The company made the assertion following the release of partial data from a phase I trial related to safety and humoral response (which relates to the drug’s potential to induce immunity).

hVIVO builds on position of strength in challenge trials

The update on the hVIVO inoculation was released by the National Institutes of Health (NIH), which shared the new information to American Society of Tropical Medicine and Hygiene's annual conference in New Orleans.

"The presentation of these partial preliminary results by NIH at the conference is encouraging regarding safety and immunogenicity responses,” said chairman Trevor Phillips.

“We look forward to seeing the full data when the NIH completes the sample analyses in due course, at which point, a full assessment of the trial results will be possible".

The remaining primary and secondary results from the phase I study “will be evaluated once the full and final data are available”, said hVIVO.

View full HVO profile View Profile

hVIVO PLC Timeline

Newswire
September 02 2016

Related Articles

car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use